Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Preclinical Research on MGD006 DART(R) Molecule Published in Science Translational Medicine

— MGD006 Enables T Cells to Recognize and Kill Leukemia Cells — Research Paved the Way for Human Clinical Trials ROCKVILLE, Md., May 27, 2015...
May 13, 2015 17:01 ET | Source: MacroGenics, Inc.

MacroGenics Announces Presentation at ASCO Annual Meeting 2015

ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...
May 06, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results

-- Company's third bi-specific DART® molecule, MGD010, in clinical testing -- FDA clears IND for fourth DART, MGD011 – Janssen to initiate clinical testing -- Margetuximab Phase 3...
April 29, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of First Quarter 2015 Financial Results Conference Call

ROCKVILLE, Md., April 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Wednesday, May 6, 2015, the Company will release its financial results for the quarter ended...
April 28, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Announces Participation in Two Investor Conferences in May

ROCKVILLE, Md., April 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
April 20, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Presents Pre-Clinical Data on its Multivalent DR5 DART at the AACR Annual Meeting

ROCKVILLE, Md., April 20, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
April 16, 2015 16:48 ET | Source: MacroGenics, Inc.

MacroGenics Announces Presentations at AACR Annual Meeting 2015

ROCKVILLE, Md., April 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
April 07, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the 14th Annual Needham Healthcare Conference

Rockville, MD, April 7, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...
March 16, 2015 07:00 ET | Source: MacroGenics, Inc.

MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders

ROCKVILLE, Md., March 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
March 03, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and 2014 Financial Results

-- Four oncology molecules in clinical development, including two bi-specific DART® molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash...